Evidence map›Paper›PMID 37309005›Full record

ArticleClinical epigenetics2023

Comprehensive DNA methylation profiling of COVID-19 and hepatocellular carcinoma to identify common pathogenesis and potential therapeutic targets.

Huiyan Luo, Jixin Chen, Qiyin Jiang, Yifan Yu, Miaolun Yang, Yuehua Luo, Xiongwen Wang

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Huiyan LuoThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jixin ChenThe Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Qiyin JiangThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yifan YuThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Miaolun YangThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuehua LuoThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiongwen WangDepartment of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. awen681029@163.com.
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThe effects of SARS-CoV-2 infection can be more complex and severe in patients with hepatocellular carcinoma (HCC) as compared to other cancers. This is due to several factors, including pre-existing conditions such as viral hepatitis and cirrhosis, which are commonly associated with HCC.

methodsWe conducted an analysis of epigenomics in SARS-CoV-2 infection and HCC patients, and identified common pathogenic mechanisms using weighted gene co-expression network analysis (WGCNA) and other analyses. Hub genes were identified and analyzed using LASSO regression. Additionally, drug candidates and their binding modes to key macromolecular targets of COVID-19 were identified using molecular docking.

resultsThe epigenomic analysis of the relationship between SARS-CoV-2 infection and HCC patients revealed that the co-pathogenesis was closely linked to immune response, particularly T cell differentiation, regulation of T cell activation and monocyte differentiation. Further analysis indicated that CD4

conclusionsIn this research, we conducted an epigenomics analysis to identify common pathogenetic processes between SARS-CoV-2 infection and HCC patients, providing new insights into the pathogenesis and treatment of HCC patients infected with SARS-CoV-2.

Indexed as

Carcinoma, HepatocellularCOVID-19Liver NeoplasmsCell Cycle ProteinsDNA MethylationEpoxide HydrolasesHumansMicrotubule-Associated ProteinsMolecular Docking SimulationSARS-CoV-2Cell Cycle ProteinsEPHX4 protein, humanEpoxide HydrolasesFAM83D protein, humanMicrotubule-Associated ProteinsCOVID-19DNA methylationHepatocellular carcinoma (HCC)Hub genesPrognosisSARS-CoV-2

Identifiers

PMID37309005
PMCPMC10259366
OpenAlexW4380421930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.